Evidence map›Paper›PMID 28069655›Full record

ArticleAntimicrobial agents and chemotherapy2017

Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.

Pankaj Kumar, Amit Kaushik, Drew T Bell, Varsha Chauhan, Fangfang Xia, Rick L Stevens, Gyanu Lamichhane

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Microbiology spectrum · 2023
    Article
  2. Are the Newer Carbapenems of Any Value against Tuberculosis.Antibiotics (Basel, Switzerland) · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. BioMed research international · 2018
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pankaj KumarCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Amit KaushikCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Drew T BellCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Varsha ChauhanTaskforce To Study Resistance Emergence & Antimicrobial Development Technology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Fangfang XiaArgonne National Laboratory, Argonne, Illinois, USA.
Rick L StevensTaskforce To Study Resistance Emergence & Antimicrobial Development Technology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Gyanu LamichhaneCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA lamichhane@jhu.edu.ORCID 0000-0002-2214-0114
Johns Hopkins University · USArgonne National Laboratory · US

Funding

New Drug for Treatment of Chronic Bacterial InfectionDP2OD008459 · OD · JOHNS HOPKINS UNIVERSITY · PI LAMICHHANE, GYANU · 2011 to 2013
$2.6M
Mutations that Confer Mycobacteria Resistance to CarbapenemsR03AI128132 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LAMICHHANE, GYANU · 2017 to 2017
$82k
NIAID NIH HHS HHSN272201400027CNIAID NIH HHS R03 AI128132NIH HHS DP2 OD008459
6 · The paper itself

Abstract

β-Lactams are the most widely used antibacterials. Among β-lactams, carbapenems are considered the last line of defense against recalcitrant infections. As recent developments have prompted consideration of carbapenems for treatment of drug-resistant tuberculosis, it is only a matter of time before

Indexed as

DNA, IntergenicMutationAmino Acid SequenceAmino Acid SubstitutionAnti-Bacterial AgentsBacterial ProteinsBase Sequencebeta-Lactam ResistanceCephalosporinsClavulanic AcidGene ExpressionGenetic LociHumansMeropenemMicrobial Sensitivity TestsMycobacterium tuberculosisAnti-Bacterial AgentsBacterial ProteinsbiapenemCephalosporinsClavulanic AcidDNA, IntergenicMeropenemnitrocefinThienamycinsantibiotic resistancecarbapenemsMycobacterium tuberculosis

Identifiers

PMID28069655
PMCPMC5328524
OpenAlexW2568501028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.